

AMEDISYS INC
Form 8-K
April 06, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 6, 2015
Commission File Number: 0-24260

Amedisys, Inc.
(Exact Name of Registrant as specified in its Charter)

Delaware **11-3131700**
(State or other jurisdiction of **(I.R.S. Employer**
incorporation or organization) **Identification No.)**
5959 S. Sherwood Forest Blvd., Baton Rouge, LA 70816
(Address of principal executive offices, including zip code)
(225) 292-2031 or (800) 467-2662
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 5 Corporate Governance and Management

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Effective April 15, 2015, Michael O. Fleming, Chief Medical Officer of Amedisys, Inc. (the Company), will depart the Company to pursue other opportunities. Dr. Fleming will receive severance compensation in accordance with the provisions in his Employment Agreement, as amended, regarding termination without cause or resignation for good reason, as described in the Company's Proxy Statement for its 2014 Annual Meeting of Stockholders, as filed with the Securities and Exchange Commission on April 30, 2014.

The Company expects to enter into a consulting agreement with Dr. Fleming on mutually acceptable terms to assist with the transition of his responsibilities.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDISYS, INC.

By: /s/ Paul B. Kusserow

Paul B. Kusserow

President and Chief Executive Officer

DATE: April 6, 2015